TRGT Share Price

Open 1.35 Change Price %
High 1.35 1 Day -0.68 -41.46
Low 0.82 1 Week 0.00 0.00
Close 0.96 1 Month 0.00 0.00
Volume 197793 1 Year 0.00 0.00
52 Week High 274.40
52 Week Low 87.16
TRGT Important Levels
Resistance 2 1.45
Resistance 1 1.25
Pivot 1.04
Support 1 0.67
Support 2 0.47
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Targacept, Inc. (NASDAQ: TRGT)

TRGT Technical Analysis 5
As on 20th Aug 2015 TRGT Share Price closed @ 0.96 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.54 & Strong Sell for SHORT-TERM with Stoploss of 2.60 we also expect STOCK to react on Following IMPORTANT LEVELS.
TRGT Target for November
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TRGT Other Details
Segment EQ
Market Capital 139070800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.targacept.com
TRGT Address
TRGT
100 North Main Street
Suite 1510
Winston-Salem, NC 27101
United States
Phone: 336-480-2100
Fax: 336-480-2107
TRGT Latest News
Interactive Technical Analysis Chart Targacept, Inc. ( TRGT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Targacept, Inc.
TRGT Business Profile
Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas. The Company's drug discovery activities utilize computer-based molecular design methodologies and biological and chemical data for a library of diverse compounds developed and collected. The Company refers to these technologies collectively as Pentad. Its clinical-stage product candidates include TC-5214, TC-5619, TC-6987, AZD3480 (TC-1734), AZD1446 (TC-6683), TC-6499 and TC-6987.